OBJECTIVE: Brain arteriovenous malformations (bAVMs) are an important cause of hemorrhagic stroke. The underlying mechanisms are not clear. No animal model for adult bAVM is available for mechanistic exploration. Patients with hereditary hemorrhagic telangiectasia type 2 (HHT2) with activin receptor-like kinase 1 (ALK1; ACVRL1) mutations have a higher incidence of bAVM than the general population. We tested the hypothesis that vascular endothelial growth factor (VEGF) stimulation with regional homozygous deletion of Alk1 induces severe dysplasia in the adult mouse brain, akin to human bAVM. METHODS: Alk1(2f/2f) (exons 4-6 flanked by loxP sites) and wild-type (WT) mice (8-10 weeks old) were injected with adenoviral vector expressing Cre recombinase (Ad-Cre; 2 × 10(7) plaque forming units [PFU]) and adeno-associated viral vectors expressing VEGF (AAV-VEGF; 2 × 10(9) genome copies) into the basal ganglia. At 8 weeks, blood vessels were analyzed. RESULTS: Gross vascular irregularities were seen in Alk1(2f/2f) mouse brain injected with Ad-Cre and AAV-VEGF. The vessels were markedly enlarged with abnormal patterning resembling aspects of the human bAVM phenotype, displayed altered expression of the arterial and venous markers (EphB4 and Jagged-1), and showed evidence of arteriovenous shunting. Vascular irregularities were not seen in similarly treated WT mice. INTERPRETATION: Our data indicate that postnatal, adult formation of the human disease, bAVM, is possible, and that both genetic mutation and angiogenic stimulation are necessary for lesion development. Our work not only provides a testable adult mouse bAVM model for the first time, but also suggests that specific medical therapy can be developed to slow bAVM growth and potentially stabilize the rupture-prone abnormal vasculature.
OBJECTIVE:Brain arteriovenous malformations (bAVMs) are an important cause of hemorrhagic stroke. The underlying mechanisms are not clear. No animal model for adult bAVM is available for mechanistic exploration. Patients with hereditary hemorrhagic telangiectasia type 2 (HHT2) with activin receptor-like kinase 1 (ALK1; ACVRL1) mutations have a higher incidence of bAVM than the general population. We tested the hypothesis that vascular endothelial growth factor (VEGF) stimulation with regional homozygous deletion of Alk1 induces severe dysplasia in the adult mouse brain, akin to human bAVM. METHODS:Alk1(2f/2f) (exons 4-6 flanked by loxP sites) and wild-type (WT) mice (8-10 weeks old) were injected with adenoviral vector expressing Cre recombinase (Ad-Cre; 2 × 10(7) plaque forming units [PFU]) and adeno-associated viral vectors expressing VEGF (AAV-VEGF; 2 × 10(9) genome copies) into the basal ganglia. At 8 weeks, blood vessels were analyzed. RESULTS: Gross vascular irregularities were seen in Alk1(2f/2f) mouse brain injected with Ad-Cre and AAV-VEGF. The vessels were markedly enlarged with abnormal patterning resembling aspects of the human bAVM phenotype, displayed altered expression of the arterial and venous markers (EphB4 and Jagged-1), and showed evidence of arteriovenous shunting. Vascular irregularities were not seen in similarly treated WT mice. INTERPRETATION: Our data indicate that postnatal, adult formation of the human disease, bAVM, is possible, and that both genetic mutation and angiogenic stimulation are necessary for lesion development. Our work not only provides a testable adult mouse bAVM model for the first time, but also suggests that specific medical therapy can be developed to slow bAVM growth and potentially stabilize the rupture-prone abnormal vasculature.
Authors: C A Potter; J Armstrong-Wells; H J Fullerton; W L Young; R T Higashida; C F Dowd; V V Halbach; S W Hetts Journal: J Neurointerv Surg Date: 2009-10-23 Impact factor: 5.836
Authors: S Matsubara; J L Mandzia; K ter Brugge; R A Willinsky; M E Faughnan; J L Manzia Journal: AJNR Am J Neuroradiol Date: 2000 Jun-Jul Impact factor: 3.825
Authors: Azeb Tadesse Argaw; Blake T Gurfein; Yueting Zhang; Andleeb Zameer; Gareth R John Journal: Proc Natl Acad Sci U S A Date: 2009-01-27 Impact factor: 11.205
Authors: Amy L Akers; Eric Johnson; Gary K Steinberg; Joseph M Zabramski; Douglas A Marchuk Journal: Hum Mol Genet Date: 2008-12-16 Impact factor: 6.150
Authors: Rose Du; Tomoki Hashimoto; Tarik Tihan; William L Young; Victor Perry; Michael T Lawton Journal: J Neurosurg Date: 2007-03 Impact factor: 5.115
Authors: Marwa Mahmoud; Kathleen R Allinson; Zhenhua Zhai; Rachael Oakenfull; Pranita Ghandi; Ralf H Adams; Marcus Fruttiger; Helen M Arthur Journal: Circ Res Date: 2010-03-11 Impact factor: 17.367
Authors: Yi Guo; Tara Saunders; Hua Su; Helen Kim; Deniz Akkoc; David A Saloner; Steven W Hetts; Christopher Hess; Michael T Lawton; Andrew W Bollen; Tony Pourmohamad; Charles E McCulloch; Tarik Tihan; William L Young Journal: Stroke Date: 2012-02-02 Impact factor: 7.914
Authors: Li Ma; Fanxia Shen; Kristine Jun; Chen Bao; Robert Kuo; William L Young; Stephen L Nishimura; Hua Su Journal: Transl Stroke Res Date: 2016-06-29 Impact factor: 6.829
Authors: Chul Han; Se-Woon Choe; Yong Hwan Kim; Abhinav P Acharya; Benjamin G Keselowsky; Brian S Sorg; Young-Jae Lee; S Paul Oh Journal: Angiogenesis Date: 2014-06-24 Impact factor: 9.596
Authors: Shantel Weinsheimer; Ari D Brettman; Ludmila Pawlikowska; D Christine Wu; Michael R Mancuso; Frank Kuhnert; Michael T Lawton; Stephen Sidney; Jonathan G Zaroff; Charles E McCulloch; William L Young; Calvin Kuo; Helen Kim Journal: Transl Stroke Res Date: 2012-08-14 Impact factor: 6.829
Authors: Wanqiu Chen; Yi Guo; Espen J Walker; Fanxia Shen; Kristine Jun; S Paul Oh; Vincent Degos; Michael T Lawton; Tarik Tihan; Dimitrios Davalos; Katerina Akassoglou; Jeffrey Nelson; John Pile-Spellman; Hua Su; William L Young Journal: Arterioscler Thromb Vasc Biol Date: 2012-12-13 Impact factor: 8.311